159 related articles for article (PubMed ID: 12481416)
21. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
[TBL] [Abstract][Full Text] [Related]
22. Differential sensitivity of human and mouse alkyltransferase to O6-benzylguanine using a transgenic model.
Liu L; Lee K; Wasan E; Gerson SL
Cancer Res; 1996 Apr; 56(8):1880-5. PubMed ID: 8620508
[TBL] [Abstract][Full Text] [Related]
23. Acquired resistance to O6-benzylguanine plus chloroethylnitrosoureas in human breast cancer.
Phillips WP; Gerson SL
Cancer Chemother Pharmacol; 1999; 44(4):319-26. PubMed ID: 10447580
[TBL] [Abstract][Full Text] [Related]
24. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
[TBL] [Abstract][Full Text] [Related]
25. Synergistic efficacy of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone.
Gerson SL; Zborowska E; Norton K; Gordon NH; Willson JK
Biochem Pharmacol; 1993 Jan; 45(2):483-91. PubMed ID: 8435098
[TBL] [Abstract][Full Text] [Related]
26. Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice.
Bibby MC; Thompson MJ; Rafferty JA; Margison GP; McElhinney RS
Br J Cancer; 1999 Mar; 79(9-10):1332-9. PubMed ID: 10188873
[TBL] [Abstract][Full Text] [Related]
27. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Mitchell RB; Dolan ME
Cancer Chemother Pharmacol; 1993; 32(1):59-63. PubMed ID: 8462125
[TBL] [Abstract][Full Text] [Related]
28. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
[TBL] [Abstract][Full Text] [Related]
29. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
30. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
Dolan ME; Pegg AE; Moschel RC; Grindey GB
Biochem Pharmacol; 1993 Jul; 46(2):285-90. PubMed ID: 8347150
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Cancer Chemother Pharmacol; 2000; 45(1):69-77. PubMed ID: 10647505
[TBL] [Abstract][Full Text] [Related]
32. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
Mitchell RB; Moschel RC; Dolan ME
Cancer Res; 1992 Mar; 52(5):1171-5. PubMed ID: 1737376
[TBL] [Abstract][Full Text] [Related]
33. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
Marathi UK; Dolan ME; Erickson LC
Cancer Res; 1994 Aug; 54(16):4371-5. PubMed ID: 8044784
[TBL] [Abstract][Full Text] [Related]
34. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Bacolod MD; Johnson SP; Pegg AE; Dolan ME; Moschel RC; Bullock NS; Fang Q; Colvin OM; Modrich P; Bigner DD; Friedman HS
Mol Cancer Ther; 2004 Sep; 3(9):1127-35. PubMed ID: 15367707
[TBL] [Abstract][Full Text] [Related]
35. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea.
Pegg AE; Swenn K; Chae MY; Dolan ME; Moschel RC
Biochem Pharmacol; 1995 Oct; 50(8):1141-8. PubMed ID: 7488227
[TBL] [Abstract][Full Text] [Related]
36. Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine.
Xu-Welliver M; Leitão J; Kanugula S; Meehan WJ; Pegg AE
Biochem Pharmacol; 1999 Oct; 58(8):1279-85. PubMed ID: 10487529
[TBL] [Abstract][Full Text] [Related]
37. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Friedman HS; Keir ST; Houghton PJ
Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457
[TBL] [Abstract][Full Text] [Related]
38. Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.
Gerson SL; Phillips W; Kastan M; Dumenco LL; Donovan C
Blood; 1996 Sep; 88(5):1649-55. PubMed ID: 8781420
[TBL] [Abstract][Full Text] [Related]
39. Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Friedman HS; Dolan ME; Pegg AE; Marcelli S; Keir S; Catino JJ; Bigner DD; Schold SC
Cancer Res; 1995 Jul; 55(13):2853-7. PubMed ID: 7796412
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
